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The objective of this paper was to prepare and provide resources to pharmacists and other healthcare 
professionals, enabling them to carry out a critical analysis on drug abuse, acquiring knowledge in several 
areas that effectively contribute to their personal development in this professional field. Professionals play 
a crucial role in the reduction and prevention of substances abuse, since they are able to advise patient about 
illicit drugs, psychotropic medicines and alcohol abuse. There is an urgent need to specialize pharmacists 
to act in the national public health service and contribute to actions aimed at the surrounding community.
Uniterms: Pharmaceutical professional. Drugs/abuse. Drugs/dependence. Public health.
Esse artigo tem o intuito de preparar e fornecer subsídios a farmacêuticos e outros profissionais de saúde 
a realizarem uma análise crítica sobre o abuso de drogas adquirindo conhecimento em diversas áreas que 
contribuam para o seu próprio desenvolvimento nesse campo de atuação. O profissional é fundamental 
na redução e prevenção ao abuso de substâncias, pois é capaz de aconselhar pacientes sobre o abuso de 
drogas ilícitas, medicamentos psicotrópicos e álcool. Há urgência na especialização de farmacêuticos 
para atuarem na saúde pública nacional contribuindo nas ações dirigidas à comunidade.
Unitermos: Profissional farmacêutico. Drogas/abuso. Drogas/dependência. Saúde pública.
INTRODUCTION
Despite scientific advances and continuous creation 
of novel clinical methods, the complex problem of drug 
abuse and dependence is growing. It is not possible to de-
termine if an individual will become drug dependent, and 
the consumption of psychoactive substances among youths 
and adults from all economic backgrounds is prevalent.
In Brazil, problems related to psychoactive substan-
ce consumption are a major concern, a fact demonstrated 
by transversal epidemiologic studies conducted at elemen-
tary or grade school, high school and higher education 
institutions in Brazil. The information about drug use in 
a given population assists and defines the type of inter-
vention that should be developed. In order to implement 
such actions, there is a need for specific knowledge about 
the evolution of use of given substances within particular 
settings, as well as working descriptions of current pre-
vention programs in place (Andrade et al., 1997, Galduróz 
et al., 2005, Stempliuk et al., 2005, Carlini et al. 2006, 
SENAD, 2007).
According to data published in the ‘World Drugs 
Report’ of 2007, issued by the United Nations Organiza-
tion (UNO), cocaine use in Brazil increased from 0.4% (in 
2001) to 0.7% (in 2005) while marijuana use also increa-
sed. Marijuana was the illicit drug presenting the highest 
increase in use over recent years, having risen from 1% 
in 2001 to 2.6% in 2005. The UNO considers this rise a 
reflection of the drug’s availability in Brazil (WDR, 2007).
An effective policy can act to reduce problems rela-
ted to alcohol and other drugs consumption experienced 
by a given society. To this end, the “Policy of the Ministry 
of Health for Integral Care of Alcohol and Other Drugs 
Users” in which it “assumes integrally and articulately 
the challenge to prevent, treat and rehabilitate users of 
alcohol and other drugs, as a public health problem” 
(Brasil, 2004) requires the creation, at a national level, of 
multidisciplinary health teams to intervene in the health-
disease process of dependents. (Machado, Miranda, 2007).
In Brazil, no previous studies have investigated 
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pharmacists’ conditions or qualifications to tackle drug 
abuse and dependence (Pepe, Castro, 2000). The pream-
ble of the ‘Code of Ethics for the Pharmacist Profession’ 
elucidates the necessity of knowledge and actions from 
this professional in all public health fields, when stating 
“The pharmacist is a healthcare professional, charged 
with performing activities inherent to the pharmaceutical 
professional sphere, so as to safeguard public health, 
including the provision of educational actions aimed at 
the local community for health promotion purposes” 
(Conselho Federal de Farmácia, 2004).
In this context, the qualification of healthcare profes-
sionals is essential to enable them to act in the spheres of 
prevention and treatment. With regard to pharmacists, this 
need has been demonstrated in some international studies, 
mainly citing the Pharmacy practice and teaching about 
substance abuse (Busto et al., 1994; Dole, Tommasello, 
2002; Tommasello, 2004).
These previous studies have revealed that pharma-
cists receive scant information on substance abuse during 
their undergraduate courses, and few professionals from 
this area can be considered experts on the subject. In addi-
tion, the results demonstrate that the role of this professio-
nal in reducing and preventing substance abuse could lie 
in the pharmacist-patient interaction during psychotropic 
medication dispensation (Fleming et al., 2001; Grahan et 
al., 1999; Roberts, Hunter, 2004).
For these professionals, to attain an understanding of 
the different biochemical mechanisms of action associated 
to all complex psychosocial concepts generally involved 
in the development of dependence as a disease is a stimu-
lating challenge. In the undergraduate course of Pharmacy, 
as naturally expected, the biochemical, toxicological and 
pharmacological knowledge is focused on other areas, 
while psychosocial issues are given secondary importan-
ce. This article seeks to prepare pharmacists to cope with 
situations in which the presence of dependent individuals 
occurs, and to update pharmacists, as well as other heal-
thcare professionals interested in this theme by providing 
guidance to professionals on critical analyses about drug 
abuse, and on acquiring knowledge in several areas that 
can effectively contribute to their personal development 
in this field of activity.
Basic concepts of drug abuse and dependence
Dependence is defined as a chronic brain disease 
(AMERICAN PSYCHATRIC ASSOCIATION, 1994) 
characterized by the search and compulsive use (inability 
to resist drug cravings) of a given substance, for which the 
individual despises the effect or adverse events produced 
by its consumption. Dependence is considered a brain 
disease because, generally, the consumed drugs act on the 
Central Nervous System (CNS) altering its functioning 
with respect to cerebral structures and activity (Koob et 
al., 2004). These changes can persist and lead to dangerous 
behaviors or loss of control (O´Brien, 2006; NIDA, 2007; 
Moreau, 2008).
Some variables act simultaneously in the sense of 
effectively influencing the probability of an individual 
becoming drug dependent or simply of abusing a given 
drug. These variables can be divided into: agent (drug); 
host (user) and environment. How, or the way in which, 
an individual becomes dependent, is related to their per-
sonal vulnerability. Generally, a number of risk factors 
are associated to the development of this disease, such as 
drug availability, its cost, administration route, toxicoki-
netics and dynamics, heredity, innate tolerance, speed of 
development of acquired tolerance, mental disturbances, 
social status, group pressure, primary and secondary rein-
forcement, and conditioned stimulations (O´Brien, 2006; 
NIDA, 2007; Moreau, 2008).
The tolerance and abstinence syndrome are very 
important symptoms to diagnose drug dependence. Ho-
wever, these are not the sole symptoms to characterize the 
condition (Moreau, 2008). Tolerance is the most common 
response to repeated use of a single drug and can be defi-
ned as a decrease in response to the drug, after prolonged 
administration, that is, the individual requires a higher 
drug dose to obtain the same effect previously experien-
ced. The abstinence syndrome is a combination of signs 
and symptoms occurring upon sudden discontinuation of 
drug use. These signs are physical and may occur due to 
two main factors: use interruption or CNS hyperactivity 
resulting from readaptation to the drug causing the depen-
dence (O´Brien, 2006; NIDA, 2007).
Another very important concept related to drug 
abuse is the reinforcement potential. This is defined as 
the capacity a drug possesses to generate repeated self-
administration without requiring other external induction 
mechanisms. Some drugs possess higher or lower positive 
reinforcements and, without doubt, those providing most 
pleasant and faster rewards are most reinforced because 
they stimulate self-administration more intensely (Moreau, 
2008).
There are several types of abuse drugs. In Brazil, 
there are licit (or legal) drugs, such as alcohol, tobacco and 
psychotropic medications, as well as illicit (illegal) drugs, 
such as marijuana, cocaine, ecstasy, crack and LSD. These 
drugs do not act on the CNS in the same way. Each drug 
possesses specific mechanisms of action and interactions, 
as evidenced in Table I.
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TABLE I – Drug classification and the main characteristics that should be known by the pharmacist professional and other health 
care professionals. (NIDA, 2007; Almeida, Lima, 2008; Cazenave, Costa, 2008; Chasin, Silva, Carvalho, 2008; Galvão, Galvão, 
Moreau, 2008; Moreau, 2008; Oliveira, Camargo, 2008; Scivoletto, Malbergier, Pileggi, 2008)
Drug Classification Licit/illicit
Administration 
path
Mechanism of action Effects
Reinforcement 
potential
Does it cause 
dependence?
Heroin Opiate Illicit
Intravenous, 
nasal or inhaled
Interaction between the 
drug and endogenous 
opioid receptors
Supraspinal analgesia, 
respiratory depression, 
euphoria and myosis
High Yes
Cocaine Stimulant Illicit
Intravenous and 
nasal (powder) 
or inhaled 
(crack)
Transient elevation 
of concentrations 
of Norepinephrine 
and Dopamine with 
subsequent decrease to 
values below normal 
range
Reactivity, humor, emotion 
and stereotyped behavior, 
tachycardia and mydriasis. 
Euphoria followed by 
depression
High Yes
Amphetamines Stimulant
Illicit (MDA 
ecstasy, rebites) and 
licit (anorexigen 
regulated by 
Ordinance  # 
344/98)
Oral
Act as sympathomimetic 
amines in the a and b 
adrenergic receptors
Agitation, irritability, 
insomnia, trembling, 
diaphoresis, tachycardia, 
mydriasis and redness.
High Yes
Marijuana (D-9 
THC)
Cannabis
Illicit  (marijuana, 
skank, hashish)
Inhaled
Interaction of D-9 
THC with cannabinoid 
and endocannabinoid 
receptors (CB1 and 
CB2). Their euphoric 
and dependence producer 
mechanisms are still very 
little known.
Euphoria, followed by 
relaxation, somnolence or 
depression, loss of time 
and space discrimination 
and decreased motor 
coordination. Tachycardia, 
red eyes, appetite increase 
(“larica”) and mouth 
dryness
High
The prolonged 
use could lead 
the dependence, 
but there are 
controversies in the 
diagnostic criteria 
of disease (DSM 
IV)
Ethanol 
(alcoholic 
beverages)
Depressor Licit Oral (intake)
Increases the synaptic 
inhibition mediated 
by GABA and by 
chloride flux. Acts in 
other neurotransmitter 
systems, such as 
adrenergic and opioid 
systems, in the release of 
serotonin, acetylcholine, 
glutamate and calcium
Sedation, anxiety decrease, 
doughy speech, ataxia, 
judging ability and 
behavioral disinhibition.
High Yes
Nicotine Tobacco Licit Inhaled
Agonist of nicotinic 
receptor of acetylcholine 
in the peripheral and 
central nervous system
Central and motor 
stimulation, cardiac 
frequency and blood 
pressure elevation.
Lower than  that 
of cocaine and 
amphetamines
Yes
LSD Hallucinogenic Illicit Oral
Specific stimulation 
of serotonin receptors 
5-HT1 and 5HT-2
Hallucinations, physical, 
time, space sensation and 
affective modifications.
High Yes
Ecstasy Hallucinogenic Illicit Oral
Increases the 
liberation of at least 
3 neurotransmitters 
in the synaptic cleft: 
serotonin, dopamine and 
noradrenalin
Increase of euphoria and 
well-being; sharpened 
sensorial perception, 
improved sociability, 
increase of intimacy 
sensation and proximity to 
other people.
High Yes
Barbiturics Depressor
Licit  (regulated 
by Ordinance # 
344/98)
Oral (hypnotic 
and sedative) 
Intravenous 
(induction or 
maintenance 
of anesthesia 
or epilepsy 
treatment)
Strengthening of GABA 
action in the pre- and 
post-synaptic GABA
A
 
receptor 
Depression, light sedation 
and hypnosis to deep coma.
High Yes
Benzodiazepines Depressor
Licit  (regulated 
by Ordinance # 
344/98)
Oral
Interaction with Central 
Nervous System 
receptors placed in 
parallel to GABA 
receptors, strengthening 
the activity of this 
neurotransmitter.
Depression High Yes
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National epidemiologic studies
The epidemiologic studies about drugs seek to: (i) 
ascertain the use of given drugs in a population of interest, 
(ii) determine the factors influencing such use, and (iii) 
study the actual impact of actions proposed to prevent their 
use. These surveys possess direct influence in the devising, 
creation and implementation of national public policies. 
In Brazil, the majority of epidemiologic studies consist of 
prevalence studies, that is, the proportion of cases over a 
given time, in a specific population.
These studies are generally promoted by the organs 
responsible for their development, which are universities 
or entities linked to university research groups and official 
government organs. Some of these studies are dissemi-
nated by the National Antidrug Secretariat (Secretaria 
Nacional Antidrogas – SENAD) on its Internet gateway 
(www.senad.gov.br), or in the form of scientific articles 
(Carlini-Contrim, Gazal-Carvalho, Gouveia, 2004; Gal-
duróz et al., 2005; Carlini, 2006).
Numbering among the most important of these initia-
tives are the studies run by the Brazilian Center for Infor-
mation on Psychotropic Drugs (Centro Brasileiro de Infor-
mações sobre Drogas Psicotrópicas – CEBRID), SENAD 
and the University of São Paulo (USP). In the II National 
Survey on Psychotropic Drug Use in Brazil, run in 2005 
by CEBRID, several conclusions are relevant to healthcare 
professionals. Briefly, the prevalence of in-life use of any 
drug, except for tobacco and alcohol, had the highest rates 
in the Northwestern region, where 27.6% of interviewees 
had previously used drugs. The region with lowest in-life* 
use was the Northern region, with 14.4% drug use. In Bra-
zil overall, the in-life use for any drug (except tobacco and 
alcohol) was 22.8%. This percentage is very similar to that 
reported for Chile (23.4%) and is almost half the rate found 
in North America (USA) (45.8%) (Carlini, 2006).
With respect to Brazilian college students, the most 
relevant studies are concentrated at the University of 
São Paulo, where the evaluation of drugs consumption 
prevalence had previously taken place in 1996 and 2001. 
The comparison of these studies between the two periods 
revealed considerable changes in the behavior for and 
consumption of psychoactive substances. The patterns of 
use became more diversified with a significant increase 
in the in-life consumption of alcoholic beverages (from 
88.5% to 91.9%), tobacco (from 42.8% to 50.5%), ma-
rijuana (from 31.3 to 35.3%) and hallucinogenic agents 
(from 6.1% to 11.4%)(Andrade et al., 1997; Stempliuk 
et al., 2005). Female students began consuming more to-
bacco, marijuana, anticholinergic agents, inhaling agents 
and continued to be the highest consumers of tranquilizer 
drugs and amphetamines (Wagner et al., 2007; Wagner, 
Andrade, 2008).
In 2007, the National Antidrug Secretariat (SENAD) 
published a report evaluating alcohol consumption in the 
Brazilian population. This study found that the regular use 
of alcoholic beverages by teenagers starts at 14.8 years of 
age, and by young adults at 17.3 years of age. These figu-
res were obtained after filtering out young adults that had 
began consumption after 18 years old, that is, thus pointing 
to a decrease in the average age that young Brazilian adults 
start alcohol consumption (SENAD, 2007).
Epidemiologic studies are useful in characterizing 
the profile of a given population. The knowledge of this 
aspect, for the pharmacist professional, helps in the de-
cision taking regarding the development of a prevention 
program in their community, or in their catchment region.
Brazilian legislation and health policies on drugs
The Brazilian Legislation on Drugs has changed 
in recent years. Law No. 6368, in force since 1976, was 
superseded by Law # 11343, of August 23rd, 2006, which 
contained important modifications with respect to illicit 
drugs users, their treatment and criminalization. Law No. 
6368/76 favored the consolidation and amplification of the 
powers of institutional juridical apparatus in order to control 
drug use and trafficking, by means of the creation of relevant 
institutional spaces in the field of healthcare and Justice, 
such as the creation of treatment centers (Brasil, 2006). 
Law No. 11343, of August 23rd, 2006, instituted the 
National System of Public Policies on Drugs (Sistema 
Nacional de Políticas Públicas sobre Drogas – SISNAD), 
prescribing measures of prevention, attention and social 
reinsertion of drug users and dependents, and maintaining 
the function of defining crimes related to trafficking and 
unauthorized production of illicit drugs. In the SISNAD, 
the National Antidrug Secretariat (SENAD) is the executive 
organ responsible for health actions aimed at drugs depen-
dents, whereas the health sector, the Unified Health System 
(Sistema Único de Saúde – SUS) is the entity responsible for 
provision of integral health care assistance to all Brazilian 
citizens, including drug dependents (Brasil, 2004, 2006).
Under SUS, the assistance to alcohol and drugs users 
is formed by a network of integral healthcare assistance 
to patients, with activities related to prevention, health 
promotion and protection, besides networks formed by 
specialized entities, known as Centers for Psychosocial 
*The prevalence of drugs use is measured by the following variables: in-life use, use in the last twelve months and use in the last thirty days.
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Assistance “alcohol and drugs” (Centros de Atenção Psi-
cossocial “álcool e drogas” – CAPSad), and non-specia-
lized organs (basic health units, family health programs 
and hospitals) (Machado, Miranda, 2007).
With regard to the National Agency of Health Sur-
veillance, one of its goals is to protect the health of the ge-
neral population, as well as to uphold its legal attributions. 
To this end, Ordinance No. 344, of May 12th was created 
with the purpose of monitoring and supervising the sale of 
products and medications subject to special control (Brasil, 
1998). This ordinance was improved in 2007, with the 
creation of the National System of Management of Con-
trolled Products, according to Resolution No. 27, of March 
30th, 2007, which “considers the necessity to disseminate 
information, in its diverse levels of detail, with respect to 
commerce and use of substances and medications subject 
to special control for opportune decision taking of the 
appropriate authorities in the ambit of the National System 
of Health Surveillance” (Brasil, 2007). In this ordinance, 
there are lists of medications and substances subject to 
control, including psychotropic medications, narcotics 
and precursors in the production of abused drugs, such as 
organic solvents (Brasil, 1998).
Professional performance
In Brazil, the governmental initiatives for the re-
formulation of the university curriculum for future phar-
macist professionals, does not encompass the inclusion 
of themes such as substances abuse, dependence and 
preventive actions. There is no such study or focus on drug 
abuse on Brazilian undergraduate courses.
Generally, these themes are addressed in discussions 
of the different disciplines, such as Public Health and To-
xicology. Pharmacists interested in the subject are obliged 
to pursue graduate courses in areas other than their own 
(Psychiatry, Psychobiology, Psychology, etc.) in order to 
act as agents multiplying information on the theme. Di-
fferentiated from the national curriculum, The American 
Association of Colleges of Pharmacy has made mandatory 
the implementation of a study guide for pharmacists on 
drugs dependence and abuse in 1991, in order to bring 
these professionals closer to the reality on drugs (Dole, 
Tommasello, 2002).
In this context, we sought to describe the ideal role 
of pharmacists and the forms of activity in different areas 
of drug abuse and dependence.
Prevention
The prevention of drugs use entails interventions 
aimed at decreasing the probability of occurrence of health 
problems associated to drugs consumption. According 
to the World Health Organization (WHO), interventions 
related to prevention of drugs use are characterized into 
three levels: primary, secondary and tertiary (WHO, 1992).
In primary prevention, there is a conjunction of 
actions intended to prevent drugs use, aimed at lowering 
the chance of further individuals starting to use drugs. In 
secondary prevention, there is a conjunction of actions 
intended to prevent the occurrence of complications in 
occasional users. These measures seek to identify the 
users and promote changes in their behavior. In tertiary 
prevention, the focus is on those who make abusive use 
of drugs. These actions seek to prevent additional loss 
and/or to reintegrate individuals presenting more serious 
problems into society (WHO, 1992).
In view of the existence of several models of pre-
vention, it is fitting to emphasize that the most important 
criterion to choose the most adequate intervention in each 
circumstance and context, is previous knowledge on, and 
respect for, the characteristics of the communities within 
which the initiative is intended to act. The strategies for 
damage reduction are deployed in this context, because 
besides being present at the tertiary level of prevention 
for instance, when providing new syringes and needles to 
dependent patients infected with HIV, they also affect the 
primary and secondary levels, when promoting strategies 
of ‘anti drink driving’ or when informing young students 
regarding the importance of use of condoms after alcohol 
and drugs consumption at parties.
According to Dole and Tomasello (2002), there are 
several forms of action of the pharmacist professional in 
the prevention of drug abuse, in roles under the three mo-
dels determined by WHO. When trained, the pharmacists 
are healthcare professionals whom, by means of direct 
contact with the patient are able to: assist in dependence 
or abuse diagnosis, making use of interview instruments; 
create for instance, a list of programs of dependence treat-
ment in their neighborhood or work place; create in their 
community, a support group for patients harboring the 
disease, intervening directly with these patients through 
motivational interviews or as multiplier agents of preven-
tion and, mainly, participating in multidisciplinary health 
teams assisting these patients and taking information to 
their families about drugs and their respective harmful 
effects. (Dole, Tommasello, 2002).
Treatment
Majority of the studies and investigations on phar-
macist professional actions to combat psychoactive subs-
tances abuse and dependence are related to pharmaceutical 
care provided to patients making use of medications 
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for treatment of compulsion (for instance, methadone, 
bupropion, naltrexone, benzodiazepines) (Pepe, Castro, 
2000; Fleming et al., 2001; Carlini, Nappo, 2003; Ro-
berts, Hunter, 2004; Tommasello, 2004). In these studies, 
the pharmacist is a professional possessing a privileged 
position to provide information about drug abuse and 
dependence to other professionals of multidisciplinary 
health teams (Pepe, Castro, 2000; Fleming et al., 2001; 
Roberts, Hunter, 2004).
As previously outlined, dependence is a chronic 
brain disease requiring treatment and follow-up, for the 
rest of the life of the affected individual. Treatment of 
dependence generally involves a combination of therapies:
·	 Medication therapy: Use of some classes of medi-
cations in different phases of the disease, aiming 
to help the patient to stop drug consumption, to 
remain in treatment and to prevent recurrence. 
The role of the pharmacist professional includes 
providing orientation to patients (pharmaceutical 
care) concerning the possibility of developing 
dependence on the medications used. It is impor-
tant to emphasize that these medications, used in 
isolation, are unable to treat dependence where 
there is always the need for follow-up or non-
pharmacological intervention (NIDA, 2007). The 
utilized medications are controlled by Ordinance 
No. 344/98 and belong to the classes of narcotics 
(A1), psychotropics (B1) or “other medications 
subject to special control” (C1). These include: 
bupropion, methadone, buprenorfine, naltrexone, 
disulfiram, acamprosate (Brasil, 1998).
·	 Behavioral therapy: this helps in the engagement 
of dependent individuals, modifying their attitudes 
and behaviors in the event of stressing circumstan-
ces, environments of consumption and compulsion. 
This therapy extends the length of time individuals 
remain in treatment and raises the effectiveness of 
medication treatment and includes: Cognitive Beha-
vioral Therapy, Motivational Interviews and Group 
Therapy (NIDA, 2007).
Some investigations have demonstrated that the 
participation of a pharmacist professional in these stages 
of treatment of dependent patients was extremely satisfac-
tory, particularly when related to medication dispensation 
and pharmacovigilance of them. In Ireland and England, 
the presence of a pharmacist professional was essential in 
the follow-up of patients making use of methadone to treat 
for heroin dependence. Ranking among the most impor-
tant activities, are those related to damage reduction, in 
which the pharmacist professionals helps in the injection 
of medication, controls the needles and the amount of me-
dication administered, besides exercising greater control 
of medication and better follow-up of patient treatment 
(Fleming et al., 2001; Roberts, Hunter, 2004).
Additionally, pharmacist professionals could act 
in Pharmaceutical Care, promoting information on the 
correct form of administration of antidepressive and 
anxiolytic agents, or by applying follow-up protocols for 
patients in use of medications whose history could help 
the multidisciplinary team accompanying these patients 
or simply by promoting Pharmacovigilance. In term of 
the multidisciplinary team, the pharmacist could help this 
team by providing these other professionals with know-
ledge on drugs’ mechanisms of action, toxicokinetics, 
dynamics, pharmacological interaction and adverse reac-
tions. Besides this activity, pharmacist professionals could 
even help in the choice of pharmacotherapy and avoid 
possible erroneous use of medications. They could also 
act by clarifying the information regarding the processes 
of detoxification of patients for a particular drug, or on 
abstinence crises and interactions in the event of overdose 
in patients (Dole, Tommasello, 2002).
Toxicological analyses
It is known that analytical toxicology deals with 
the detection of chemical agents or parameters related 
to toxicant exposition, with the purpose of preventing or 
diagnosing intoxications. In this context, toxicological 
analysis is a safe conduct to identify the exposition to dru-
gs, irrespective of the characteristics in connection with the 
type of consumption, because the currently used methods 
present sufficient sensitivity and specificity to identify, in 
biological samples, the psychoactive substances present 
in drugs and/or their biotransformation products (Bass, 
Vamvakas, 2000; Silva, Tawil, 2008).
According to Decree No. 85878, of April 7th, 1981, 
one of the duties of the pharmacist professional is the 
TABLE II – Types of prevention and strategies (OMS, 1992).
Prevention Strategies
Primary Divulgence of information, sportive and cultural 
activities, change of environmental behavior 
inhibiting experimentation.
Secondary Learning of new attitudes and more responsible 
behaviors.
Tertiary Treatment of Abstinence Syndrome, treatment of 
overdoses, hospital attendance of intoxications, 
forwarding and follow-up of dependents families 
and help for social rehabilitation of dependents. 
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performing of functions, assistance and technical responsi-
bility in “organs, laboratories, sectors of pharmaceutical 
establishments in which quality control and/or inspection 
are developed, previous analysis, control analysis and fis-
cal analysis of products having therapeutic or anesthetic 
nature, or that are diagnosis auxiliaries, or able to deter-
mine physical or psychic dependence”. In addition to these 
functions, in Article 2nd there are some duties inherent to 
professionals which are not private, the most relevant of 
these being “organs and laboratories or establishments in 
which examinations of chemical-toxicological character 
are developed…” (Brasil, 1981).
Today, pharmacist professionals do not act only in 
toxicological analyses. In clinical toxicology, for instan-
ce, they are also involved in a great number of medical 
practices. The increase of such professionals in these 
services helps, besides other activities, in the creation of 
health policies against drug abuse, pharmacovigilance and 
poisoning (Chyka, 2007). Toxicological analysis could 
be considered yet another area of action for pharmacist 
professionals wishing to work in this context. The duties 
of pharmacist professional include helping in the diagnosis 
and monitoring of dependent patients’ treatment.
FINAL CONSIDERATIONS
Ultimately, pharmacist professionals are respon-
sible for choosing their own vocation within the profes-
sion, but as healthcare professionals they have a duty to 
acquire basic knowledge on drug abuse and dependence. 
This is because for these professionals, contact, even if 
minimal, with the population, albeit within commer-
cial establishments exercising technical responsibility, 
universities conducting investigations and training new 
professionals, or even in hospitals and laboratories where 
clinical and toxicological analyses are performed, places 
them in a privileged position of adviser, confidant and 
guide.
The pharmacist professional has to be prepared in 
order to deal with different psychosocial issues of drug 
abuse and dependence, and to exercise their professional 
role as a health agent. To this end, investigations into the 
development of this human resource should be carried out 
and specialization courses for the different types of pro-
fessional action in this area should be stimulated, aiming 
at future placement of more pharmacist professionals 
into multidisciplinary health teams, who can intervene in 
the health-disease process of dependent individuals and 
contribute to the development of increasingly effective 
prevention programs in the national milieu.
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